The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Background: Heart failure is a complex and multifactorial disease that affects millions globally, posing significant challenges to healthcare systems.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...

Atrial fibrillation, or A-fib, is an irregular heart rhythm that increases a person's risk of stroke, heart failure and even ...

The addition of β-adrenergic antagonists to the treatment regimen for heart failure has validated the neurohormonal hypothesis and provided much-improved outcomes. This benefit had been in ...

Preliminary findings from an 18-month study on acute coronary syndromes, conducted across several hospitals in Kuwait and ...

Sleepiness at the wheel is a significant contributing factor to motor vehicle accidents. A new analysis published in ...

The following is a summary of “Unmasking High-Output Heart Failure: Beyond Conventional Paradigms,” published in the January ...

Peripheral edema is a not too uncommon finding with direct vasodilators and in most cases of treatment with these drugs does not reflect developed CHF. The authors of the original publication ...

A well-marbled steak is highly prized for grilling, but those sort of fat deposits in human muscles can be deadly, a ...